このアプリケーションの一部のコンテンツは現時点では利用できません。
このような状況が続く場合は、にお問い合わせくださいフィードバック & お問い合わせ
1. (WO2014140930) COMPOSITIONS AND METHODS FOR ENHANCING THE THERAPEUTIC POTENTIAL OF STEM CELLS
注意: このテキストは、OCR 処理によってテキスト化されたものです。法的な用途には PDF 版をご利用ください。

CLAIMS

1. A composition comprising a population of cells and a non-mwsele myosin II antagonist for use is treating a disease amenable to treatment with stem cell therapy

2. Composition according to claim 1 , wherein the disease is selected from the group of, a disease that is a result of diabetes, a disease that is a result of atherosclerosis, a vascular disease, a peripheral artery disease (PAD).

3. Composition according to claim 1 or 2, wherein the disease is associated with an ankle brachial pressure index of about or less than 0.9, or an ankle brachial pressure index of about or less than 0.7.

4. Composition according to claims 1 to 3, wherein the disease has resulted in critical limb ischemia and/or the disease has resulted in skin ulcerations or gangrene.

5. Composition according to claims 1 to 4, wherein a portion of the population of cells comprises pluripotent colls and/or, wherein the pluripotent cells are induced pluripotent stem cells, and/or, wherein a portion of the population of cells comprises muitipotent cells and/or, wherein the multipotent cells are multipotent stromal cells or mesenchymal stem cells and/or, wherein the multipotent cells are derived from induced pluripotent stem cells.

6. Composition of claims 1 to 5, wherein the limb function in the patient improves by about or at least 2-3 grades compared to the same patient not receiving the composition and/or, the limb blood flow in the patient improves to about or at least 65-85% of untreated limb blood flow, and/or the ischemic damage in the patient improves by about or at least 2, 3 or 4 grades compared to the same patient not receiving the composition.

7. Composition according to claims 1 to 6, wherein the non-muscle myosin II antagonist is selected from the group of,

an siRNA targeted to knock down non-muscle myosm II gene and/οr protein expression,

a DNA vector encoding an siRNA,

miRNA or anti -sense RN A targeted to knock down non-muscle myosin If gene and/or protein expression,

an angiotensin If receptor antagonist or angiotensin receptor blocker, an angiotensin-converting-enzyme (ACE) inhibitor,

2,3-butanedione-2-monoxime (BDM),

blebbistatin or an analog, derivative or variant thereof,

is pyaolidinone derivative and,

a molecule from the class of pyrrolidinones,

8. A kit for treating a disease amenable to treatment with stem cell therapy comprising:

a. a non-muscle myosin If antagonist:

b, optionally a pharmaceutically acceptable carrier; and

c. optionally instructions for administering items (a) -(c) to a patient diagnosed with cardiovascular disease.

d. a population of multipotent cells;

9. The kit of claim 8 wherein the cells are MSCs.

10. The kit of claims 8 or 9, wherein the non-muscle myosin If antagonist is blebbistatin,

1 1. A stem cell composition, for treating a disease amenable to treatment with stem cell therapy comprising a population of multipotent cells; and a non -muscle myosin II antagonist

12. The composition of claim I L wherein the cells are MSCs.

1 3. The composition of claim 11 or 12 wherein the non-mnsele myosia IT antagonist is blebbistatin.

14. A method of making a stem cell composition for treating a disease amenable to treatment with stem cell therapy comprising a population of multipotent cells; and a non-musele myosin II antagonist; wherein the population of multipotent cells md the NM if antagonist are incubated together for period of time prior to administration to a patient.

15. Composition comprising a population of multipotent cells: and a non-musele .myosin II antagonist for use in a healing process in a disease asneadable to healing and amenable to a treatment with a stem cell therapy, wherein the composition results in healing of the disease faster than the same composition, lacking the a non-muscle myosin it antagonist

16. Composition of claim 15, wherein the cells are MSCs and/or, the NM If antagonist is blebbistatin and/or, the disease is a eardiovascular disease.